Journal of International Psychiatry

[Abstract] Objective To explore the therapeutic effect of amisulpride and paroxetine in patients with major depression, and to analyze the effect on synapse-related miRNAs expression. Methods From April 2018 to October 2019, 124 patients with severe depression diagnosed who treated in our hospital were divided into observation group (odd number) and control group (even number) according to digital parity method, 62 cases each. All patients received conventional treatment and paroxetine treatment. Patients in the observation group were treated with amisulpride on this basis. Both groups were treated for 3 months, detected the expression level of synapse-related miRNAs (miR-124, miR-132, miR-134, miR-138), negative symptom rating scale (SANS) scores and adverse reactions. Results After 3 months of treatment, the expression levels of miR-124, miR-134 and miR-138 in the observation group were lower than those in the control group, and the expression levels of miR-132 were higher than the control group (P<0.05); the observation group was lower than the control group (P<0.05); during the treatment, the incidence of adverse reactions was similar between the two groups (P>0.05). Conclusion Patients with severe depression benefit significantly from the treatment of amisulpride and paroxetine. The expression of synaptic-related miRNAs in patients was significantly improved, which was conducive to the improvement of negative symptoms. Combined medication will not increase the incidence of adverse reactions, it has high safety and value of clinical application.